View on market: Stay Cautious, be with quality business:

Asian equities were muted at the open on Tuesday ahead of the looming Federal Reserve interest-rate hike on Wednesday, amid moderation in crude oil prices to $96 per barrel and key corporate earnings. Futures rose in Japan, Australia and Hong Kong, while US futures declined after a choppy Wall Street session. At 6:40 am, the Singapore-traded SGX Nifty — an early barometer of India’s benchmark Nifty 50 — fell 0.27% to 16,574. Elsewhere, bitcoin dropped below $22,000.

Economic Calendar:

  • USD : New Home Sales (Jun) 26th July, 2022
  • USD : CB Consumer Confidence (Jul) 26th July, 2022
  • INR : Federal Fiscal Deficit (Jun) 29th July, 2022
  • INR : M3 Money Supply 27th July, 2022

Q1FY23 Result Today: Aditya Birla Sunlife AMC, Asian Paints, Bajaj Auto, KEI Industries, L&T, Relaxo Footwears, Sanofi India, Shoppers Stop, Symphony, Tata Power, UTI AMC, Union Bank, Ujjivan Small Finance Bank

Q1FY23 Result:

Tata Steel Q1 FY23(Consolidated, YoY) reported nearly 13% YoY decline in consolidated profit at Rs 7,765 crore for the quarter ended June 2022, impacted by higher input cost and tax expenses. Revenue during the quarter increased by 18.6% YoY to Rs 63,430 crore during the quarter. Consolidated EBITDA stood at Rs 15,047 crore, despite the sharp rise in input costs especially coking coal and gas prices in Europe, down by 7 percent YoY.

Axis Bank Q1 FY23 (Consolidated, YoY) clocked 91% YoY growth in profit at Rs 4,125 crore driven by lower provisions, but other income fell 11% and pre-provision operating profit declined 5% YoY. Net interest income grew by 21% to Rs 9,384 crore during the same period.

Tech Mahindra Q1 FY23 (Consolidated, YoY) reported a 24.8% sequential decline in consolidated profit at Rs 1,132 crore for the quarter ended June 2022 impacted by weak operating performance. Revenue grew by 4.9% QoQ to Rs 12,708 crore during the same period and EBITDA fell 10% QoQ to Rs 1,880 crore. Dollar revenue grew by 1.5% QoQ to $1,632 million and revenue growth in constant currency was 3.5% QoQ.

Brokerage Radar:

JPM ON AXIS BANK: Neutral, TP cut to Rs 780 from Rs 880

Loan growth disappoints with 1% q/q decline; Retail does better, corporate slower

NIM improvement guidance maintained

ROAs at 1.4% remain 60bps lower vs larger peers, which could remain a drag on vals


Cut FY23-26E EPS estimates by up to 6% due to lower margins to a/c for 1QFY23

EBIT margin at 11.0% missed GSe est at 11.6% due to which EBIT missed GSe by c.2%


Consol EBITDA beat– EU surprises +vely

While EU EBITDA/ton surprised +vely, as lagged impact of a steel price hike was reflected during qtr, expecting profitability to decline in 2H FY23 given a recent correction of EU steel prices

International Markets:

U.S & Europe:

Particulars      25th July Chg. Chg.(%)
Nasdaq 11,782.67 -51.44 -0.43
Dow 31,990.04 90.75 0.28
FTSE 7,306.30 29.93 0.41
CAC 6,237.55 20.73 0.33
DAX 13,210.32 -43.36 -0.33
Dow Fut.* 31,884.90 -105.1 -0.33

Asian markets:

Particulars      26th July Chg. Chg.(%)
SGX Nifty 16,598.50 -20 -0.12
Nikkei 27,681.73 -17.52 -0.06
Straits Times 3,180.98 0.51 0.02
Hang Seng 20,814.18 251.24 1.22
Shanghai 3,270.82 20.43 0.63

ADR Watch:

Particulars    25th July Chg. Chg.(%)
Dr. Reddy 55.84 0.57 1.03
HDFC Bank 59.15 0.54 0.92
ICICI Bank 20.08 0.00 0.00
Infosys 18.56 -0.32 -1.69
Tata Motor 28.01 -0.18 -0.64
Wipro 5.18 0.04 0.78

Commodities & Currency:

Particulars Current Price Chg.(%)
USD/INR 79.73 -0.16
Brent 102 1.81
Gold 1723.80 0.27
Silver 18.43 0.56


Particulars 25th July 22nd July
FIIs -844.78 -675.45
DIIs -72.26 739.38

News Update:

Lupin: The pharma company has received approval from US FDA for its abbreviated new drug application (ANDA), Azilsartan Medoxomil tablets, to market a generic equivalent of Edarbi tablets of Azurity Pharmaceuticals Inc, in the US. The product will be manufactured at Lupin’s facility in Nagpur, India.

Sun Pharmaceutical Industries: Life Insurance Corporation of India has offloaded 4.8 crore equity shares or 2% stake in the company via open market transactions during May 17-July 22, 2022. With this, LIC’s stake in the company reduced to 5.02%, from 7.02% earlier.

Strides Pharma Science: The company said the Committee of Directors approved offering for subscription, on a private placement basis, up to 1,500 senior, secured, rated, unlisted, redeemable, non-convertible debentures (NCDs) of face value Rs 10 lakh each aggregating up to Rs 150 crore.

Source: Moneyontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL